Patent
Botulinum toxin screening assays
Reads0
Chats0
TLDR
In this article, the authors present methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT receptor binding and methods for reducing BoNT-A activity.Abstract:
Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to FGFR3 to a governmental or regional regulatory authority.read more
Citations
More filters
Patent
Clostridial toxin pharmaceutical compositions
Gopal Dasari,Ananda Seneviratne,Jack Z. Xie,Huong T. Tran,Alex Praseuth,Don Mathewson,Terrence J. Hunt,Harish P.M. Kumar +7 more
TL;DR: In this article, animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostrichial toxin active ingredient and at least two excipients are presented.
Patent
Immuno-Based Botulinum Toxin Serotype A Activity Assays
Ester Fernandez-Salas,Joanne Wang,Patton E. Garay,Lina S. Wong,D. Dianne Hodges,Kei Roger Aoki +5 more
TL;DR: In this paper, a method of detecting anti-BoNT/A neutralizing antibodies was proposed, which was directed to a method to detect anti-rabidus neutralization.
Patent
Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
Lance E. Steward,Ester Fernandez-Salas,Joseph Francis,Shengwen Li,Marcella A. Gilmore,Kei Roger Aoki +5 more
TL;DR: In this paper, the authors describe modified Clostridial toxins comprising a Clostrianial toxin enzymatic domain, a Closterial toxin translocation domain, and an enhanced Clostriansial toxin binding domain.
Patent
Fret protease assays for clostridial toxins
TL;DR: In this paper, a clostridial toxin recognition sequence was presented, where the cleavage site intervened between the donor fluorophore and the acceptor under the appropriate conditions, resonance energy transfer was exhibited.
Patent
Multivalent Clostridial toxins
Lance E. Steward,Ester Fernandez-Salas,Joseph Francis,Shengwen Li,Marcella A. Gilmore,Kei Roger Aoki +5 more
TL;DR: In this paper, a multivalent Clostridial toxin comprising more than one binding domain directed to a cell surface molecule of a target cell is used as therapeutic composition to prevent exocytosis and secretion by the target cell.
References
More filters
Journal ArticleDOI
Fibroblast growth factors, their receptors and signaling.
TL;DR: FGF signaling also appears to play a role in tumor growth and angiogenesis, and autocrine FGF signaling may be particularly important in the progression of steroid hormone-dependent cancers to a hormone-independent state.
Journal ArticleDOI
Crystal structure of botulinum neurotoxin type A and implications for toxicity.
TL;DR: The crystal structure of the entire 1,285 amino acid di-chain neurotoxin was determined and the toxin appears as a hybrid of varied structural motifs and suggests a modular assembly of functional subunits to yield pathogenesis.
Journal ArticleDOI
SV2 is the protein receptor for botulinum neurotoxin A.
Min Dong,Felix L. Yeh,William H. Tepp,Camin Dean,Eric A. Johnson,Roger Janz,Edwin R. Chapman +6 more
TL;DR: It is found that BoNT/A enters neurons by binding to the synaptic vesicle protein SV2 (isoforms A, B, and C), and SV2 acts as the protein receptor for Bo NT/A.
Journal ArticleDOI
Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons.
Neil R. Cashman,Heather D. Durham,Jan Krzysztof Blusztajn,Kenichiro Oda,Takeshi Tabira,Ivan T. Shaw,Simone Dahrouge,Jack P. Antel +7 more
TL;DR: A series of mouse‐mouse neural hybrid cell lines developed by fusing the aminopterin‐sensitive neuroblastoma N18TG2 with motor neuron‐enriched embryonic day 12–14 spinal cord cells appear to model selected aspects of motor neuron development in an immortalized clonal system.
Journal ArticleDOI
How botulinum and tetanus neurotoxins block neurotransmitter release.
TL;DR: How the proteolytic attack at specific sites of the targets for BoNTs and TeNT induces perturbations of the fusogenic SNARE complex dynamics and how these alterations can account for the inhibition of spontaneous and evoked quantal neurotransmitter release by the neurotoxins are explained.